ACR GUIDELINES Bundle (free trial)

Juvenile Idiopathic Arthritis - Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis and Systemic JIA

American College of Rheumatology GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1512423

Contents of this Issue

Navigation

Page 3 of 13

4 Treatment Table 2. Classes of Interventions Nonsteroidal anti-inflammatory drugs (NSAIDs) Any at therapeutic dosing (Ibuprofen, Naproxen, Tolmetin, Indomethacin, Meloxicam, Nabumetone, Diclofenac, Piroxicam, Etodolac, Celecoxib) Conventional synthetic disease- modifying antirheumatic drugs (DMARDs) Methotrexate (MTX), Sulfasalazine (SSZ), Hydroxychloroquine (HCQ), Leflunomide (LEF), Calcineurin inhibitors (cyclosporin A, tacrolimus) Biologic disease-modifying antirheumatic drugs (DMARDs) • Tumor necrosis factor alpha inhibitors (TNFi): Adalimumab, Etanercept, Infliximab, Golimumab, Certolizumab pegol • Other biologic response modifiers (OBRM): Abatacept, Tocilizumab, Anakinra, Canakinumab Glucocorticoids (GC) • Oral: Any • Intravenous: Any • Intra-articular: Triamcinolone Acetonide, Triamcinolone Hexacetonide

Articles in this issue

Archives of this issue

view archives of ACR GUIDELINES Bundle (free trial) - Juvenile Idiopathic Arthritis - Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis and Systemic JIA